Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ: ACAD )

18.67 -0.41 (-2.15%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
ACADIA Pharmaceuticals's Return On Capital Employed Insights
ACADIA Pharmaceuticals (NASDAQ:ACAD) brought in sales totaling $115.47 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 162.35%, resulting in a loss of $113.06... 
Via Benzinga
ACADIA Pharmaceuticals: Q1 Earnings Insights
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
ACADIA Pharmaceuticals's Earnings Outlook
ACADIA Pharmaceuticals (NASDAQ:ACAD) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Expert Ratings For ACADIA Pharmaceuticals
ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis
Via Benzinga
Futures Flat As Yen Discombobulation Extends To Record 13th Day
After some jerky rollercoaster moves in Monday's illiquid trading session, which jerked both higher and lower before closing modestly in the green. 
Via Talk Markets
What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter: 
Via Benzinga
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time to start off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
23 Stocks Moving in Tuesday's Pre-Market Session
Gainers ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss. Sharps Technology, Inc. (NASDAQ: STSS... 
Via Benzinga
Why Acadia Pharma Shares Are Falling Today
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million. 
Via Benzinga
28 Biggest Movers From Yesterday
Gainers SailPoint Technologies Holdings, Inc. (NYSE: SAIL) shares jumped 29.16% to close at $64.05 on Monday after private equity firm Thoma Bravo announced plans to acquire... 
Via Benzinga
Stocks That Hit 52-Week Highs On Thursday
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high... 
Via Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
Acadia: Helping With Alzheimers And Parkinsons
Things always change fast in biotech, but until recently things have been moving consistently to the downside. It’s been a while, but we believe this is finally over. And we believe Acadia... 
Via Talk Markets
Stocks And Oil Drop Following The Weak Job Report
It was a strange day for the market that started with a big miss on the ADP job report. 
Via Talk Markets
9 Monster Stock Market Predictions For The Week Of March 28
It will be a critical week for stocks after weeks of gains. The S&P 500 finished Friday in an exciting spot and at more than one inflection point. It may mark the start of a bigger run higher to the... 
Via Talk Markets
Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating
Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91. 
Via Investor's Business Daily
Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today
We're taking a look at the top stock news for Wednesday and that includes the latest analysts upgrades and downgrades you need to know about! 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022
Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Gain; All Eyes On Fed Decision
Pre-open movers U.S. stock futures traded higher in early pre-market trade ahead of the interest rate decision from the Federal Reserve. Investors are awaiting earnings results... 
Via Benzinga
Expert Ratings For ACADIA Pharmaceuticals
Over the past 3 months, 18 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks... 
Via Benzinga
Recap: ACADIA Pharmaceuticals Q4 Earnings
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Acadia Resubmits Pimavanserin US Application For Expanded Use In Alzheimer's Psychosis
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has resubmitted its FDA supplemental marketing application for pimavanserin for hallucinations and delusions associated... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022
Upgrades According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.